Therapeutic efficacy of slow-release allopurinol in gout and hyperuricaemia
Dunky, A.; Nitsche, V.; Eberl, R.
Wiener Klinische Wochenschrift 93(2): 65-68
1981
ISSN/ISBN: 0043-5325 PMID: 7245774 Document Number: 173039
The efficacy of a slow-release preparation of allopurinol is verified by biochemical, pharmacological and clinical investigations. The action of a 300 mg allopurinol tablet, with normal release and absorption parameters, is based on the specific activity of oxypurinol, a metabolite which is formed from allopurinol according to a biotransformation process. The inhibitory action of oxypurinol on xanthine oxidase amounts to only 1/5 that of allopurinol. Allopurinol shows an extremely short half-life, so that a slow-release preparation of allopurinol seems the better way of administration to achieve adequate uricostatic efficacy with a single dose over a 24 h period.